Dr. Ossama M. Maher, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2013
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
FL license ME131868 · OK license 43185
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Nicklaus Children's Hospital Miami, FL
Medical groups
- Kidz Medical Services Inc (24 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rezurock (belumosudil mesylate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 31 payments worth $4,282 in total to this clinician.
| Day One Biopharmaceuticals | $3,068 |
|---|---|
| Novartis Pharmaceuticals Corporation | $292 |
| Alexion Pharmaceuticals, Inc. | $238 |
| Sanofi-aventis U.S. LLC | $150 |
| Incyte Corporation | $147 |
| Springworks Therapeutics, Inc. | $80.37 |
| Sobi, Inc | $78.16 |
| Rare Disease Therapeutics, Inc. | $42.66 |
| Honoraria | $2,998 |
|---|---|
| Food and Beverage | $1,109 |
| Consulting Fee | $175 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Day One Biopharmaceuticals Oct 8, 2025 | Honoraria OJEMDA · ONCOLOGY | $2,998 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $175 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $23,434 in research payments for these studies, mostly to the institutions running them.
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals · Active, not recruiting · NCT05566795
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.